Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 10, 2025
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der…
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankheiten entwickelt, …
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), …
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients atteints de maladies métaboliques graves et dont …
MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The growing challenges with traditional weight loss methods and why most diets fail What GLP-1 receptor agonists like Semaglutide and Tirzepatide are and how they support …
CTW Inc. Launches Collaboration Between Spider and Slime Anime Games
EIN Presswire
·
May 10, 2025
CTW Inc. Announces Collaboration Event Between So I'm a Spider, So What? Ruler of the Labyrinth and That Time I Got Reincarnated as a Slime MINATO-KU, TOKYO, JAPAN, May 10, 2025 /EINPresswire.com/ -- CTW Inc. has launched a collaboration event featuring …
Hotel Toiletries Market Size to worth USD 52.01 Bn by 2032, expanding at 10.4% CAGR, says Coherent Market Insights
GlobeNewswire
·
May 10, 2025
Burlingame, CA, May 10, 2025 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, The global hotel toiletries market is projected to be valued at USD 26.00 billion in 2025 and reach USD 52.01 billion by 2032, growing at a CAGR of 5.9% according to a …
ProstAfense Under Review: Military-Inspired Prostate Reset Protocol for Stronger Flow in Aging Males Over 40 (New Vaporub Trick)
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The overlooked challenges aging men face with prostate health after 40, including frequent urination and interrupted sleep Why conventional prostate health solutions may fall …
Female Vitality Blueprint Under Review: Upper Body Alignment Stretch for Women's Libido Dysfunction by Alex Miller
GlobeNewswire
·
May 10, 2025
Los Angeles, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: How female libido dysfunction often stems from overlooked physical misalignments, not just hormonal imbalances Why many standard libido treatments fall short, and the real …
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt
GlobeNewswire
·
May 10, 2025
Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose) aufgrund von MASH auf Basis von SYMMETRY-Studiendaten nach 96 Wochen, die auf dem EASL Congress 2025 …
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
GlobeNewswire
·
May 10, 2025
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 semaines de l’essai SYMMETRY ont fait l’ …
NeuroQuiet Complaints Investigated: 2025 User Reviews Tested & Verified
GlobeNewswire
·
May 10, 2025
Los Angeles, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The most common NeuroQuiet complaints and whether they hold merit based on verified user reviews. A complete breakdown of NeuroQuiet ingredients and how the formula may support …
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewswire
·
May 10, 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN …
Pelvic Floor Strong Under Review: Best Bladder Control Method for Leaking with Total Core & Pelvic Floor Repair Exercises
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why bladder leakage and pelvic floor dysfunction affect millions of women over 40 What the pelvic floor is, how it works, and why it weakens over time The common causes of pelvic …
Best Blue Light Blocking Glasses 2025: Swanwick Day & Night Orange Glasses for Improved Sleep Support
GlobeNewswire
·
May 10, 2025
Los Angeles, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The impact of blue light exposure from screens on your sleep, focus, and circadian rhythm Why digital eye strain has become a widespread problem in 2025 The science behind …
Tonic Greens Complaints Investigated: 2025 User Reviews Tested & Verified
GlobeNewswire
·
May 10, 2025
Jackson, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why Tonic Greens is one of 2025’s most searched greens powders for immune support and natural energy The most common Tonic Greens complaints and whether they reflect broader user …
Best Telomere Supplement for Longevity: Advanced Support for Healthy Telomeres
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: What telomeres are and why telomere length plays a crucial role in aging and cellular health How telomere shortening contributes to fatigue, reduced immune function, and other age …
Best Things To Do In Chicago (2025): Groupon Awarded Top Activity Finder Site By Expert Consumers
GlobeNewswire
·
May 10, 2025
NEW YORK CITY, May 10, 2025 (GLOBE NEWSWIRE) -- Expert Consumers has named Groupon as a leading online platform for discovering and booking local activities, recognizing its usability, category depth, and ongoing role in helping consumers access affordable …
TestRX: The Most Trusted & Tested Testosterone Booster for Muscle Mass Gains in Men
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: Why declining testosterone levels affect muscle mass, energy, and motivation in men The science-backed reasons men experience hormonal decline as they age How TestRX supports …
Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)
GlobeNewswire
·
May 10, 2025
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more difficult than ever. Despite trying countless diets, workout routines, and the latest supplements, many people still struggle with stubborn belly fat that just won't go …
Slimjaro Complaints 2025: Real User Reviews Analyzed & Exposed
GlobeNewswire
·
May 10, 2025
SAN JOSE, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- For years, I tried everything to lose weight—juice cleanses, trendy supplements, fat-burning powders, even those expensive “miracle” injections. But no matter what I did, the results never lasted. I’d …
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire
·
May 10, 2025
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk …